nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—stomach cancer	0.314	0.679	CbGaD
Afatinib—EGFR—stomach cancer	0.148	0.321	CbGaD
Afatinib—EGFR—Docetaxel—stomach cancer	0.112	0.418	CbGbCtD
Afatinib—ABCB1—Mitomycin—stomach cancer	0.0355	0.132	CbGbCtD
Afatinib—ABCG2—Irinotecan—stomach cancer	0.0253	0.0941	CbGbCtD
Afatinib—ABCG2—Fluorouracil—stomach cancer	0.0242	0.0903	CbGbCtD
Afatinib—ABCG2—Docetaxel—stomach cancer	0.0185	0.069	CbGbCtD
Afatinib—ABCG2—Doxorubicin—stomach cancer	0.0138	0.0514	CbGbCtD
Afatinib—ABCG2—Methotrexate—stomach cancer	0.0134	0.0498	CbGbCtD
Afatinib—ABCB1—Irinotecan—stomach cancer	0.0091	0.0339	CbGbCtD
Afatinib—ABCB1—Docetaxel—stomach cancer	0.00667	0.0249	CbGbCtD
Afatinib—ABCB1—Doxorubicin—stomach cancer	0.00497	0.0185	CbGbCtD
Afatinib—ABCB1—Methotrexate—stomach cancer	0.00482	0.018	CbGbCtD
Afatinib—ERBB2—gall bladder—stomach cancer	0.00294	0.0626	CbGeAlD
Afatinib—BLK—hematopoietic system—stomach cancer	0.00243	0.0517	CbGeAlD
Afatinib—BLK—lymphoid tissue—stomach cancer	0.00171	0.0364	CbGeAlD
Afatinib—ERBB2—hematopoietic system—stomach cancer	0.00166	0.0354	CbGeAlD
Afatinib—DYRK1A—hematopoietic system—stomach cancer	0.0016	0.0341	CbGeAlD
Afatinib—ERBB2—epithelium—stomach cancer	0.00152	0.0324	CbGeAlD
Afatinib—ERBB4—epithelium—stomach cancer	0.00152	0.0324	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—stomach cancer	0.00146	0.0312	CbGeAlD
Afatinib—Vandetanib—FYN—stomach cancer	0.00146	0.375	CrCbGaD
Afatinib—HIPK4—endocrine gland—stomach cancer	0.00139	0.0297	CbGeAlD
Afatinib—ERBB2—pancreas—stomach cancer	0.00135	0.0289	CbGeAlD
Afatinib—IRAK1—hematopoietic system—stomach cancer	0.00124	0.0265	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—stomach cancer	0.00117	0.0249	CbGeAlD
Afatinib—ERBB2—digestive system—stomach cancer	0.00116	0.0246	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—stomach cancer	0.00113	0.024	CbGeAlD
Afatinib—EPHA6—endocrine gland—stomach cancer	0.0011	0.0235	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—stomach cancer	0.0011	0.0233	CbGeAlD
Afatinib—PHKG2—endocrine gland—stomach cancer	0.00106	0.0226	CbGeAlD
Afatinib—IRAK1—pancreas—stomach cancer	0.00101	0.0216	CbGeAlD
Afatinib—BLK—lymph node—stomach cancer	0.000964	0.0205	CbGeAlD
Afatinib—PHKG2—liver—stomach cancer	0.000958	0.0204	CbGeAlD
Afatinib—ERBB2—endocrine gland—stomach cancer	0.000955	0.0204	CbGeAlD
Afatinib—ERBB4—endocrine gland—stomach cancer	0.000955	0.0204	CbGeAlD
Afatinib—Gefitinib—CHEK2—stomach cancer	0.000941	0.242	CrCbGaD
Afatinib—DYRK1A—endocrine gland—stomach cancer	0.00092	0.0196	CbGeAlD
Afatinib—ERBB2—liver—stomach cancer	0.000861	0.0184	CbGeAlD
Afatinib—DYRK1A—liver—stomach cancer	0.000829	0.0177	CbGeAlD
Afatinib—IRAK1—bone marrow—stomach cancer	0.000797	0.017	CbGeAlD
Afatinib—LCK—bone marrow—stomach cancer	0.000778	0.0166	CbGeAlD
Afatinib—DYRK1A—Topotecan—Irinotecan—stomach cancer	0.000774	0.207	CbGdCrCtD
Afatinib—PHKG2—lymph node—stomach cancer	0.000735	0.0157	CbGeAlD
Afatinib—EGFR—liver—stomach cancer	0.00073	0.0156	CbGeAlD
Afatinib—ABL1—hematopoietic system—stomach cancer	0.000697	0.0148	CbGeAlD
Afatinib—ERBB2—lymph node—stomach cancer	0.00066	0.0141	CbGeAlD
Afatinib—IRAK1—liver—stomach cancer	0.000644	0.0137	CbGeAlD
Afatinib—DYRK1A—lymph node—stomach cancer	0.000636	0.0135	CbGeAlD
Afatinib—LCK—liver—stomach cancer	0.000628	0.0134	CbGeAlD
Afatinib—ABL1—smooth muscle tissue—stomach cancer	0.000614	0.0131	CbGeAlD
Afatinib—ERBB2—Topotecan—Irinotecan—stomach cancer	0.000595	0.159	CbGdCrCtD
Afatinib—ABL1—pancreas—stomach cancer	0.000567	0.0121	CbGeAlD
Afatinib—EGFR—lymph node—stomach cancer	0.00056	0.0119	CbGeAlD
Afatinib—IRAK1—lymph node—stomach cancer	0.000494	0.0105	CbGeAlD
Afatinib—ABL1—lymphoid tissue—stomach cancer	0.00049	0.0105	CbGeAlD
Afatinib—ABL1—digestive system—stomach cancer	0.000484	0.0103	CbGeAlD
Afatinib—LCK—lymph node—stomach cancer	0.000482	0.0103	CbGeAlD
Afatinib—Vandetanib—VEGFA—stomach cancer	0.000469	0.121	CrCbGaD
Afatinib—ABL1—bone marrow—stomach cancer	0.000447	0.00952	CbGeAlD
Afatinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000444	0.119	CbGdCrCtD
Afatinib—ABCB1—blood vessel—stomach cancer	0.000407	0.00867	CbGeAlD
Afatinib—ABL1—endocrine gland—stomach cancer	0.0004	0.00853	CbGeAlD
Afatinib—Vandetanib—EGFR—stomach cancer	0.000396	0.102	CrCbGaD
Afatinib—Gefitinib—EGFR—stomach cancer	0.000376	0.0968	CrCbGaD
Afatinib—ABL1—liver—stomach cancer	0.000361	0.00769	CbGeAlD
Afatinib—ABCG2—bone marrow—stomach cancer	0.000282	0.006	CbGeAlD
Afatinib—ABL1—lymph node—stomach cancer	0.000277	0.0059	CbGeAlD
Afatinib—ABCG2—liver—stomach cancer	0.000228	0.00485	CbGeAlD
Afatinib—ABCB1—hematopoietic system—stomach cancer	0.000217	0.00462	CbGeAlD
Afatinib—ABCB1—epithelium—stomach cancer	0.000198	0.00422	CbGeAlD
Afatinib—DYRK1A—Idarubicin—Epirubicin—stomach cancer	0.000182	0.0487	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—stomach cancer	0.000182	0.0487	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—stomach cancer	0.000182	0.0487	CbGdCrCtD
Afatinib—ABCB1—pancreas—stomach cancer	0.000176	0.00376	CbGeAlD
Afatinib—ABCG2—lymph node—stomach cancer	0.000175	0.00372	CbGeAlD
Afatinib—Sepsis—Doxorubicin—stomach cancer	0.000173	0.00214	CcSEcCtD
Afatinib—Renal failure—Capecitabine—stomach cancer	0.00017	0.0021	CcSEcCtD
Afatinib—Hepatobiliary disease—Docetaxel—stomach cancer	0.000169	0.00209	CcSEcCtD
Afatinib—Stomatitis—Capecitabine—stomach cancer	0.000169	0.00208	CcSEcCtD
Afatinib—Epistaxis—Docetaxel—stomach cancer	0.000169	0.00208	CcSEcCtD
Afatinib—Conjunctivitis—Capecitabine—stomach cancer	0.000168	0.00208	CcSEcCtD
Afatinib—Urinary tract infection—Capecitabine—stomach cancer	0.000168	0.00208	CcSEcCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—stomach cancer	0.000168	0.045	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—stomach cancer	0.000168	0.045	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—stomach cancer	0.000168	0.045	CbGdCrCtD
Afatinib—Renal impairment—Epirubicin—stomach cancer	0.000165	0.00203	CcSEcCtD
Afatinib—Infection—Irinotecan—stomach cancer	0.000164	0.00202	CcSEcCtD
Afatinib—Hepatobiliary disease—Capecitabine—stomach cancer	0.000164	0.00202	CcSEcCtD
Afatinib—Epistaxis—Capecitabine—stomach cancer	0.000163	0.00201	CcSEcCtD
Afatinib—Nervous system disorder—Irinotecan—stomach cancer	0.000162	0.002	CcSEcCtD
Afatinib—Urinary tract disorder—Docetaxel—stomach cancer	0.000159	0.00196	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—stomach cancer	0.000158	0.00195	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—stomach cancer	0.000158	0.00194	CcSEcCtD
Afatinib—Infection—Fluorouracil—stomach cancer	0.000157	0.00194	CcSEcCtD
Afatinib—Nervous system disorder—Fluorouracil—stomach cancer	0.000155	0.00191	CcSEcCtD
Afatinib—Urinary tract disorder—Capecitabine—stomach cancer	0.000154	0.00189	CcSEcCtD
Afatinib—Connective tissue disorder—Capecitabine—stomach cancer	0.000153	0.00188	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—stomach cancer	0.000153	0.00325	CbGeAlD
Afatinib—Urethral disorder—Capecitabine—stomach cancer	0.000152	0.00188	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—stomach cancer	0.000152	0.00188	CcSEcCtD
Afatinib—ABCB1—digestive system—stomach cancer	0.000151	0.00321	CbGeAlD
Afatinib—Eye disorder—Docetaxel—stomach cancer	0.00015	0.00185	CcSEcCtD
Afatinib—Insomnia—Irinotecan—stomach cancer	0.000149	0.00184	CcSEcCtD
Afatinib—Dyspnoea—Irinotecan—stomach cancer	0.000147	0.00181	CcSEcCtD
Afatinib—Dehydration—Epirubicin—stomach cancer	0.000146	0.0018	CcSEcCtD
Afatinib—Eye disorder—Capecitabine—stomach cancer	0.000145	0.00179	CcSEcCtD
Afatinib—Dyspepsia—Irinotecan—stomach cancer	0.000145	0.00179	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—stomach cancer	0.000145	0.00178	CcSEcCtD
Afatinib—Dry skin—Epirubicin—stomach cancer	0.000144	0.00177	CcSEcCtD
Afatinib—Decreased appetite—Irinotecan—stomach cancer	0.000144	0.00177	CcSEcCtD
Afatinib—Insomnia—Fluorouracil—stomach cancer	0.000143	0.00176	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—stomach cancer	0.000143	0.00176	CcSEcCtD
Afatinib—Gastrointestinal disorder—Irinotecan—stomach cancer	0.000143	0.00176	CcSEcCtD
Afatinib—Fatigue—Irinotecan—stomach cancer	0.000142	0.00175	CcSEcCtD
Afatinib—Alopecia—Docetaxel—stomach cancer	0.000142	0.00175	CcSEcCtD
Afatinib—Constipation—Irinotecan—stomach cancer	0.000141	0.00174	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—stomach cancer	0.000141	0.00174	CcSEcCtD
Afatinib—Dyspnoea—Fluorouracil—stomach cancer	0.000141	0.00174	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—stomach cancer	0.000141	0.00173	CcSEcCtD
Afatinib—Mediastinal disorder—Capecitabine—stomach cancer	0.00014	0.00173	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—stomach cancer	0.00014	0.00173	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—stomach cancer	0.00014	0.0374	CbGdCrCtD
Afatinib—Malnutrition—Docetaxel—stomach cancer	0.00014	0.00172	CcSEcCtD
Afatinib—Dyspepsia—Fluorouracil—stomach cancer	0.000139	0.00172	CcSEcCtD
Afatinib—ABCB1—bone marrow—stomach cancer	0.000139	0.00296	CbGeAlD
Afatinib—Alanine aminotransferase increased—Epirubicin—stomach cancer	0.000138	0.0017	CcSEcCtD
Afatinib—Decreased appetite—Fluorouracil—stomach cancer	0.000137	0.00169	CcSEcCtD
Afatinib—Alopecia—Capecitabine—stomach cancer	0.000137	0.00169	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—stomach cancer	0.000137	0.00169	CcSEcCtD
Afatinib—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000137	0.00168	CcSEcCtD
Afatinib—Mental disorder—Capecitabine—stomach cancer	0.000136	0.00168	CcSEcCtD
Afatinib—Malnutrition—Capecitabine—stomach cancer	0.000135	0.00167	CcSEcCtD
Afatinib—Back pain—Docetaxel—stomach cancer	0.000135	0.00167	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—stomach cancer	0.000135	0.00166	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—stomach cancer	0.000134	0.00166	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—stomach cancer	0.000134	0.00166	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—stomach cancer	0.000133	0.00164	CcSEcCtD
Afatinib—Dysgeusia—Capecitabine—stomach cancer	0.000133	0.00163	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—stomach cancer	0.000132	0.00163	CcSEcCtD
Afatinib—Back pain—Capecitabine—stomach cancer	0.000131	0.00161	CcSEcCtD
Afatinib—Body temperature increased—Irinotecan—stomach cancer	0.000131	0.00161	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—stomach cancer	0.000131	0.00161	CcSEcCtD
Afatinib—Muscle spasms—Capecitabine—stomach cancer	0.00013	0.0016	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—stomach cancer	0.00013	0.0016	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—stomach cancer	0.00013	0.0016	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—stomach cancer	0.000129	0.0346	CbGdCrCtD
Afatinib—Infestation—Methotrexate—stomach cancer	0.000129	0.00159	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—stomach cancer	0.000129	0.00159	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—stomach cancer	0.000128	0.00158	CcSEcCtD
Afatinib—Renal failure—Methotrexate—stomach cancer	0.000127	0.00156	CcSEcCtD
Afatinib—Vandetanib—ALB—stomach cancer	0.000126	0.0324	CrCbGaD
Afatinib—Upper respiratory tract infection—Epirubicin—stomach cancer	0.000126	0.00155	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—stomach cancer	0.000126	0.00155	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—stomach cancer	0.000125	0.00155	CcSEcCtD
Afatinib—Body temperature increased—Fluorouracil—stomach cancer	0.000125	0.00154	CcSEcCtD
Afatinib—ABCB1—endocrine gland—stomach cancer	0.000124	0.00265	CbGeAlD
Afatinib—Weight decreased—Epirubicin—stomach cancer	0.000122	0.00151	CcSEcCtD
Afatinib—Cough—Docetaxel—stomach cancer	0.000122	0.0015	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—stomach cancer	0.000122	0.0015	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—stomach cancer	0.000122	0.0015	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—stomach cancer	0.000121	0.0015	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—stomach cancer	0.000121	0.00149	CcSEcCtD
Afatinib—Infestation—Epirubicin—stomach cancer	0.000121	0.00149	CcSEcCtD
Afatinib—Gefitinib—ALB—stomach cancer	0.00012	0.0308	CrCbGaD
Afatinib—Renal failure—Epirubicin—stomach cancer	0.000119	0.00146	CcSEcCtD
Afatinib—Asthenia—Irinotecan—stomach cancer	0.000118	0.00146	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000118	0.00146	CcSEcCtD
Afatinib—Cough—Capecitabine—stomach cancer	0.000118	0.00146	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—stomach cancer	0.000118	0.00145	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—stomach cancer	0.000117	0.00145	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—stomach cancer	0.000117	0.00145	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—stomach cancer	0.000116	0.00143	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000114	0.00141	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—stomach cancer	0.000114	0.00141	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—stomach cancer	0.000114	0.00141	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—stomach cancer	0.000114	0.0014	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—stomach cancer	0.000114	0.0014	CcSEcCtD
Afatinib—Infection—Docetaxel—stomach cancer	0.000113	0.0014	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—stomach cancer	0.000113	0.0014	CcSEcCtD
Afatinib—Diarrhoea—Irinotecan—stomach cancer	0.000113	0.00139	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—stomach cancer	0.000112	0.00138	CcSEcCtD
Afatinib—ABCB1—liver—stomach cancer	0.000112	0.00239	CbGeAlD
Afatinib—Nervous system disorder—Docetaxel—stomach cancer	0.000112	0.00138	CcSEcCtD
Afatinib—Pruritus—Fluorouracil—stomach cancer	0.000112	0.00138	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—stomach cancer	0.000112	0.00138	CcSEcCtD
Afatinib—Infestation—Doxorubicin—stomach cancer	0.000112	0.00138	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—stomach cancer	0.000111	0.00137	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—stomach cancer	0.00011	0.00135	CcSEcCtD
Afatinib—Infection—Capecitabine—stomach cancer	0.00011	0.00135	CcSEcCtD
Afatinib—Dizziness—Irinotecan—stomach cancer	0.000109	0.00135	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—stomach cancer	0.000109	0.00134	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—stomach cancer	0.000109	0.00134	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—stomach cancer	0.000109	0.00134	CcSEcCtD
Afatinib—Nervous system disorder—Capecitabine—stomach cancer	0.000108	0.00134	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—stomach cancer	0.000108	0.00133	CcSEcCtD
Afatinib—Diarrhoea—Fluorouracil—stomach cancer	0.000108	0.00133	CcSEcCtD
Afatinib—Skin disorder—Capecitabine—stomach cancer	0.000107	0.00132	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—stomach cancer	0.000107	0.00132	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—stomach cancer	0.000106	0.00131	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—stomach cancer	0.000106	0.00131	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000106	0.0013	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—stomach cancer	0.000105	0.0013	CcSEcCtD
Afatinib—Vomiting—Irinotecan—stomach cancer	0.000105	0.00129	CcSEcCtD
Afatinib—Dizziness—Fluorouracil—stomach cancer	0.000105	0.00129	CcSEcCtD
Afatinib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000104	0.028	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000104	0.028	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000104	0.028	CbGdCrCtD
Afatinib—Mediastinal disorder—Methotrexate—stomach cancer	0.000104	0.00129	CcSEcCtD
Afatinib—Rash—Irinotecan—stomach cancer	0.000104	0.00128	CcSEcCtD
Afatinib—Dermatitis—Irinotecan—stomach cancer	0.000104	0.00128	CcSEcCtD
Afatinib—Headache—Irinotecan—stomach cancer	0.000103	0.00127	CcSEcCtD
Afatinib—Insomnia—Docetaxel—stomach cancer	0.000103	0.00127	CcSEcCtD
Afatinib—Alopecia—Methotrexate—stomach cancer	0.000102	0.00126	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—stomach cancer	0.000102	0.00125	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—stomach cancer	0.000101	0.00125	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—stomach cancer	0.000101	0.00125	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—stomach cancer	0.000101	0.00124	CcSEcCtD
Afatinib—Vomiting—Fluorouracil—stomach cancer	0.000101	0.00124	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—stomach cancer	0.0001	0.00124	CcSEcCtD
Afatinib—Insomnia—Capecitabine—stomach cancer	0.0001	0.00123	CcSEcCtD
Afatinib—Rash—Fluorouracil—stomach cancer	9.97e-05	0.00123	CcSEcCtD
Afatinib—Dermatitis—Fluorouracil—stomach cancer	9.96e-05	0.00123	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—stomach cancer	9.92e-05	0.00122	CcSEcCtD
Afatinib—Headache—Fluorouracil—stomach cancer	9.91e-05	0.00122	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—stomach cancer	9.9e-05	0.00122	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—stomach cancer	9.87e-05	0.00122	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—stomach cancer	9.86e-05	0.00121	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—stomach cancer	9.85e-05	0.00121	CcSEcCtD
Afatinib—Dyspnoea—Capecitabine—stomach cancer	9.85e-05	0.00121	CcSEcCtD
Afatinib—Fatigue—Docetaxel—stomach cancer	9.84e-05	0.00121	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—stomach cancer	9.83e-05	0.00121	CcSEcCtD
Afatinib—Nausea—Irinotecan—stomach cancer	9.81e-05	0.00121	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—stomach cancer	9.77e-05	0.0012	CcSEcCtD
Afatinib—Constipation—Docetaxel—stomach cancer	9.76e-05	0.0012	CcSEcCtD
Afatinib—Back pain—Methotrexate—stomach cancer	9.75e-05	0.0012	CcSEcCtD
Afatinib—Dyspepsia—Capecitabine—stomach cancer	9.73e-05	0.0012	CcSEcCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	9.67e-05	0.0259	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	9.67e-05	0.0259	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	9.67e-05	0.0259	CbGdCrCtD
Afatinib—Decreased appetite—Capecitabine—stomach cancer	9.61e-05	0.00118	CcSEcCtD
Afatinib—Alopecia—Epirubicin—stomach cancer	9.58e-05	0.00118	CcSEcCtD
Afatinib—Gastrointestinal disorder—Capecitabine—stomach cancer	9.54e-05	0.00118	CcSEcCtD
Afatinib—Fatigue—Capecitabine—stomach cancer	9.53e-05	0.00117	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—stomach cancer	9.49e-05	0.00117	CcSEcCtD
Afatinib—Constipation—Capecitabine—stomach cancer	9.45e-05	0.00116	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—stomach cancer	9.43e-05	0.00116	CcSEcCtD
Afatinib—Nausea—Fluorouracil—stomach cancer	9.39e-05	0.00116	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—stomach cancer	9.37e-05	0.00115	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—stomach cancer	9.24e-05	0.00114	CcSEcCtD
Afatinib—Back pain—Epirubicin—stomach cancer	9.13e-05	0.00112	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—stomach cancer	9.07e-05	0.00112	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—stomach cancer	9.04e-05	0.00111	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—stomach cancer	9.02e-05	0.00111	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—stomach cancer	8.86e-05	0.00109	CcSEcCtD
Afatinib—Cough—Methotrexate—stomach cancer	8.8e-05	0.00108	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—stomach cancer	8.79e-05	0.00108	CcSEcCtD
Afatinib—Body temperature increased—Capecitabine—stomach cancer	8.74e-05	0.00108	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—stomach cancer	8.73e-05	0.00108	CcSEcCtD
Afatinib—ABCB1—lymph node—stomach cancer	8.61e-05	0.00183	CbGeAlD
Afatinib—Dysgeusia—Doxorubicin—stomach cancer	8.55e-05	0.00105	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	8.52e-05	0.00105	CcSEcCtD
Afatinib—Back pain—Doxorubicin—stomach cancer	8.44e-05	0.00104	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—stomach cancer	8.39e-05	0.00103	CcSEcCtD
Afatinib—Cough—Epirubicin—stomach cancer	8.23e-05	0.00101	CcSEcCtD
Afatinib—Asthenia—Docetaxel—stomach cancer	8.19e-05	0.00101	CcSEcCtD
Afatinib—Infection—Methotrexate—stomach cancer	8.17e-05	0.00101	CcSEcCtD
Afatinib—Pruritus—Docetaxel—stomach cancer	8.08e-05	0.000995	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—stomach cancer	8.07e-05	0.000994	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—stomach cancer	7.99e-05	0.000985	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	7.98e-05	0.000983	CcSEcCtD
Afatinib—Asthenia—Capecitabine—stomach cancer	7.93e-05	0.000977	CcSEcCtD
Afatinib—Pruritus—Capecitabine—stomach cancer	7.82e-05	0.000963	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—stomach cancer	7.81e-05	0.000962	CcSEcCtD
Afatinib—Infection—Epirubicin—stomach cancer	7.65e-05	0.000942	CcSEcCtD
Afatinib—Cough—Doxorubicin—stomach cancer	7.62e-05	0.000939	CcSEcCtD
Afatinib—Diarrhoea—Capecitabine—stomach cancer	7.56e-05	0.000932	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—stomach cancer	7.55e-05	0.00093	CcSEcCtD
Afatinib—Dizziness—Docetaxel—stomach cancer	7.55e-05	0.00093	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—stomach cancer	7.48e-05	0.000921	CcSEcCtD
Afatinib—Insomnia—Methotrexate—stomach cancer	7.44e-05	0.000917	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	7.38e-05	0.000909	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—stomach cancer	7.34e-05	0.000904	CcSEcCtD
Afatinib—Dizziness—Capecitabine—stomach cancer	7.31e-05	0.000901	CcSEcCtD
Afatinib—Vomiting—Docetaxel—stomach cancer	7.26e-05	0.000894	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—stomach cancer	7.24e-05	0.000892	CcSEcCtD
Afatinib—Rash—Docetaxel—stomach cancer	7.2e-05	0.000887	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—stomach cancer	7.19e-05	0.000886	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—stomach cancer	7.15e-05	0.000881	CcSEcCtD
Afatinib—Headache—Docetaxel—stomach cancer	7.15e-05	0.000881	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—stomach cancer	7.1e-05	0.000875	CcSEcCtD
Afatinib—Fatigue—Methotrexate—stomach cancer	7.09e-05	0.000874	CcSEcCtD
Afatinib—Infection—Doxorubicin—stomach cancer	7.08e-05	0.000872	CcSEcCtD
Afatinib—Vomiting—Capecitabine—stomach cancer	7.03e-05	0.000866	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—stomach cancer	6.99e-05	0.000861	CcSEcCtD
Afatinib—Rash—Capecitabine—stomach cancer	6.97e-05	0.000859	CcSEcCtD
Afatinib—Insomnia—Epirubicin—stomach cancer	6.96e-05	0.000858	CcSEcCtD
Afatinib—Dermatitis—Capecitabine—stomach cancer	6.96e-05	0.000858	CcSEcCtD
Afatinib—Headache—Capecitabine—stomach cancer	6.92e-05	0.000853	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—stomach cancer	6.92e-05	0.000853	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—stomach cancer	6.86e-05	0.000846	CcSEcCtD
Afatinib—Nausea—Docetaxel—stomach cancer	6.78e-05	0.000835	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—stomach cancer	6.78e-05	0.000835	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—stomach cancer	6.69e-05	0.000825	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—stomach cancer	6.65e-05	0.000819	CcSEcCtD
Afatinib—Fatigue—Epirubicin—stomach cancer	6.64e-05	0.000818	CcSEcCtD
Afatinib—Constipation—Epirubicin—stomach cancer	6.58e-05	0.000811	CcSEcCtD
Afatinib—Nausea—Capecitabine—stomach cancer	6.56e-05	0.000809	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—stomach cancer	6.5e-05	0.000801	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—stomach cancer	6.44e-05	0.000794	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—stomach cancer	6.35e-05	0.000783	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—stomach cancer	6.27e-05	0.000773	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—stomach cancer	6.19e-05	0.000763	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	6.15e-05	0.000758	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—stomach cancer	6.14e-05	0.000757	CcSEcCtD
Afatinib—Constipation—Doxorubicin—stomach cancer	6.09e-05	0.000751	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—stomach cancer	6.09e-05	0.00075	CcSEcCtD
Afatinib—Asthenia—Methotrexate—stomach cancer	5.9e-05	0.000727	CcSEcCtD
Afatinib—Pruritus—Methotrexate—stomach cancer	5.82e-05	0.000717	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—stomach cancer	5.63e-05	0.000694	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—stomach cancer	5.63e-05	0.000694	CcSEcCtD
Afatinib—Asthenia—Epirubicin—stomach cancer	5.52e-05	0.000681	CcSEcCtD
Afatinib—Pruritus—Epirubicin—stomach cancer	5.45e-05	0.000671	CcSEcCtD
Afatinib—Dizziness—Methotrexate—stomach cancer	5.44e-05	0.00067	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—stomach cancer	5.27e-05	0.000649	CcSEcCtD
Afatinib—Vomiting—Methotrexate—stomach cancer	5.23e-05	0.000645	CcSEcCtD
Afatinib—Rash—Methotrexate—stomach cancer	5.19e-05	0.000639	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—stomach cancer	5.18e-05	0.000639	CcSEcCtD
Afatinib—Headache—Methotrexate—stomach cancer	5.15e-05	0.000635	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—stomach cancer	5.11e-05	0.00063	CcSEcCtD
Afatinib—Dizziness—Epirubicin—stomach cancer	5.09e-05	0.000627	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—stomach cancer	5.04e-05	0.000621	CcSEcCtD
Afatinib—Vomiting—Epirubicin—stomach cancer	4.9e-05	0.000603	CcSEcCtD
Afatinib—Nausea—Methotrexate—stomach cancer	4.89e-05	0.000602	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—stomach cancer	4.87e-05	0.000601	CcSEcCtD
Afatinib—Rash—Epirubicin—stomach cancer	4.85e-05	0.000598	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—stomach cancer	4.85e-05	0.000598	CcSEcCtD
Afatinib—Headache—Epirubicin—stomach cancer	4.82e-05	0.000594	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—stomach cancer	4.71e-05	0.00058	CcSEcCtD
Afatinib—Nausea—Epirubicin—stomach cancer	4.57e-05	0.000564	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—stomach cancer	4.53e-05	0.000558	CcSEcCtD
Afatinib—Rash—Doxorubicin—stomach cancer	4.49e-05	0.000553	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—stomach cancer	4.49e-05	0.000553	CcSEcCtD
Afatinib—Headache—Doxorubicin—stomach cancer	4.46e-05	0.00055	CcSEcCtD
Afatinib—Nausea—Doxorubicin—stomach cancer	4.23e-05	0.000521	CcSEcCtD
Afatinib—LCK—Signaling Pathways—SMAD4—stomach cancer	3.02e-06	2.26e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—stomach cancer	3.01e-06	2.25e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—stomach cancer	3e-06	2.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6R—stomach cancer	3e-06	2.24e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—stomach cancer	2.99e-06	2.24e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—stomach cancer	2.99e-06	2.24e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK8—stomach cancer	2.98e-06	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FYN—stomach cancer	2.98e-06	2.23e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—stomach cancer	2.96e-06	2.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK3—stomach cancer	2.96e-06	2.21e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—stomach cancer	2.95e-06	2.21e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1B—stomach cancer	2.94e-06	2.2e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—stomach cancer	2.94e-06	2.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SERPINE1—stomach cancer	2.94e-06	2.2e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—stomach cancer	2.94e-06	2.2e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—stomach cancer	2.93e-06	2.19e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—stomach cancer	2.91e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—stomach cancer	2.91e-06	2.17e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—stomach cancer	2.89e-06	2.16e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6R—stomach cancer	2.89e-06	2.16e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—stomach cancer	2.89e-06	2.16e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTT1—stomach cancer	2.89e-06	2.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FYN—stomach cancer	2.87e-06	2.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2A6—stomach cancer	2.85e-06	2.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—stomach cancer	2.84e-06	2.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RHOA—stomach cancer	2.84e-06	2.12e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—stomach cancer	2.84e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—stomach cancer	2.83e-06	2.11e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—stomach cancer	2.82e-06	2.11e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK1—stomach cancer	2.82e-06	2.11e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—stomach cancer	2.82e-06	2.11e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—stomach cancer	2.81e-06	2.1e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SERPINE1—stomach cancer	2.81e-06	2.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—stomach cancer	2.81e-06	2.1e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—stomach cancer	2.81e-06	2.1e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JUN—stomach cancer	2.8e-06	2.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—stomach cancer	2.8e-06	2.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR2—stomach cancer	2.8e-06	2.09e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—stomach cancer	2.78e-06	2.08e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKR1C3—stomach cancer	2.78e-06	2.08e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAV1—stomach cancer	2.77e-06	2.07e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—stomach cancer	2.77e-06	2.07e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOA1—stomach cancer	2.77e-06	2.07e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—stomach cancer	2.76e-06	2.07e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—stomach cancer	2.76e-06	2.06e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—stomach cancer	2.73e-06	2.04e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—stomach cancer	2.72e-06	2.04e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1A—stomach cancer	2.72e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—stomach cancer	2.72e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—RHOA—stomach cancer	2.71e-06	2.03e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SERPINE1—stomach cancer	2.71e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO1—stomach cancer	2.7e-06	2.02e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—stomach cancer	2.7e-06	2.02e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR2—stomach cancer	2.69e-06	2.02e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—stomach cancer	2.69e-06	2.02e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—stomach cancer	2.68e-06	2.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—stomach cancer	2.66e-06	1.99e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK8—stomach cancer	2.65e-06	1.98e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK3—stomach cancer	2.65e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—stomach cancer	2.63e-06	1.96e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—stomach cancer	2.62e-06	1.96e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RHOA—stomach cancer	2.61e-06	1.95e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK3—stomach cancer	2.61e-06	1.95e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—stomach cancer	2.6e-06	1.94e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—stomach cancer	2.6e-06	1.94e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—stomach cancer	2.58e-06	1.93e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—stomach cancer	2.57e-06	1.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS2—stomach cancer	2.56e-06	1.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—stomach cancer	2.54e-06	1.9e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	2.53e-06	1.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK1—stomach cancer	2.52e-06	1.88e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—stomach cancer	2.52e-06	1.88e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—stomach cancer	2.52e-06	1.88e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—stomach cancer	2.51e-06	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—stomach cancer	2.5e-06	1.87e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—stomach cancer	2.49e-06	1.86e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—stomach cancer	2.49e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—stomach cancer	2.48e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—stomach cancer	2.48e-06	1.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK1—stomach cancer	2.48e-06	1.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—stomach cancer	2.48e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOA1—stomach cancer	2.48e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—stomach cancer	2.47e-06	1.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS2—stomach cancer	2.47e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—stomach cancer	2.45e-06	1.83e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—stomach cancer	2.44e-06	1.83e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—stomach cancer	2.44e-06	1.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—stomach cancer	2.43e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—stomach cancer	2.42e-06	1.81e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—stomach cancer	2.42e-06	1.81e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—stomach cancer	2.42e-06	1.81e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—stomach cancer	2.4e-06	1.8e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD44—stomach cancer	2.4e-06	1.79e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—stomach cancer	2.39e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—stomach cancer	2.39e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—stomach cancer	2.39e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOA1—stomach cancer	2.39e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—stomach cancer	2.38e-06	1.78e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—stomach cancer	2.38e-06	1.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCB—stomach cancer	2.36e-06	1.77e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—stomach cancer	2.36e-06	1.77e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6ST—stomach cancer	2.35e-06	1.76e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—stomach cancer	2.34e-06	1.75e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—stomach cancer	2.32e-06	1.74e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—stomach cancer	2.32e-06	1.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—stomach cancer	2.32e-06	1.74e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—stomach cancer	2.32e-06	1.73e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—stomach cancer	2.32e-06	1.73e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—stomach cancer	2.31e-06	1.73e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCB—stomach cancer	2.28e-06	1.7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6ST—stomach cancer	2.27e-06	1.7e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—stomach cancer	2.27e-06	1.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—stomach cancer	2.26e-06	1.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—stomach cancer	2.26e-06	1.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—stomach cancer	2.25e-06	1.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—stomach cancer	2.24e-06	1.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—stomach cancer	2.24e-06	1.67e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—stomach cancer	2.24e-06	1.67e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK1—stomach cancer	2.2e-06	1.65e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—stomach cancer	2.2e-06	1.65e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—stomach cancer	2.19e-06	1.64e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—stomach cancer	2.19e-06	1.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—stomach cancer	2.19e-06	1.63e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—stomach cancer	2.18e-06	1.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—stomach cancer	2.18e-06	1.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—stomach cancer	2.17e-06	1.62e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—stomach cancer	2.16e-06	1.62e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—stomach cancer	2.15e-06	1.61e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—stomach cancer	2.14e-06	1.6e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—stomach cancer	2.11e-06	1.58e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6R—stomach cancer	2.1e-06	1.57e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—stomach cancer	2.1e-06	1.57e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—stomach cancer	2.08e-06	1.56e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—stomach cancer	2.08e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—stomach cancer	2.07e-06	1.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—stomach cancer	2.07e-06	1.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK1—stomach cancer	2.06e-06	1.54e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPP2R1A—stomach cancer	2.04e-06	1.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6R—stomach cancer	2.02e-06	1.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—stomach cancer	2.02e-06	1.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—stomach cancer	2.02e-06	1.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—stomach cancer	2e-06	1.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—stomach cancer	2e-06	1.5e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—stomach cancer	2e-06	1.49e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—stomach cancer	1.99e-06	1.49e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—stomach cancer	1.98e-06	1.48e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—stomach cancer	1.97e-06	1.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—stomach cancer	1.97e-06	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—stomach cancer	1.95e-06	1.46e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—stomach cancer	1.94e-06	1.45e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—stomach cancer	1.92e-06	1.43e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—stomach cancer	1.91e-06	1.43e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—stomach cancer	1.91e-06	1.43e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—stomach cancer	1.91e-06	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—stomach cancer	1.91e-06	1.43e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—stomach cancer	1.91e-06	1.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RHOA—stomach cancer	1.9e-06	1.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—stomach cancer	1.9e-06	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK1—stomach cancer	1.88e-06	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—stomach cancer	1.88e-06	1.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—stomach cancer	1.86e-06	1.39e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—stomach cancer	1.86e-06	1.39e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—stomach cancer	1.84e-06	1.38e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—stomach cancer	1.84e-06	1.38e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RHOA—stomach cancer	1.83e-06	1.37e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—stomach cancer	1.83e-06	1.37e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK1—stomach cancer	1.82e-06	1.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—stomach cancer	1.82e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK1—stomach cancer	1.81e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—stomach cancer	1.81e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—stomach cancer	1.81e-06	1.35e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—stomach cancer	1.79e-06	1.34e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—stomach cancer	1.78e-06	1.33e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—stomach cancer	1.78e-06	1.33e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—stomach cancer	1.77e-06	1.32e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—stomach cancer	1.76e-06	1.32e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—stomach cancer	1.76e-06	1.31e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK1—stomach cancer	1.74e-06	1.3e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—stomach cancer	1.73e-06	1.29e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—stomach cancer	1.72e-06	1.29e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—stomach cancer	1.71e-06	1.28e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—stomach cancer	1.71e-06	1.28e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—stomach cancer	1.69e-06	1.27e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—stomach cancer	1.69e-06	1.27e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK1—stomach cancer	1.68e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—stomach cancer	1.68e-06	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—stomach cancer	1.67e-06	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—stomach cancer	1.65e-06	1.24e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—stomach cancer	1.64e-06	1.23e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—stomach cancer	1.63e-06	1.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—stomach cancer	1.63e-06	1.22e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—stomach cancer	1.62e-06	1.22e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—stomach cancer	1.6e-06	1.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—stomach cancer	1.58e-06	1.18e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—stomach cancer	1.58e-06	1.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—stomach cancer	1.58e-06	1.18e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—stomach cancer	1.57e-06	1.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	1.57e-06	1.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—stomach cancer	1.55e-06	1.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—stomach cancer	1.55e-06	1.16e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—stomach cancer	1.53e-06	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—stomach cancer	1.51e-06	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—stomach cancer	1.51e-06	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—stomach cancer	1.51e-06	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—stomach cancer	1.5e-06	1.12e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—stomach cancer	1.5e-06	1.12e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOA1—stomach cancer	1.5e-06	1.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—stomach cancer	1.5e-06	1.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—stomach cancer	1.49e-06	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—stomach cancer	1.46e-06	1.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—stomach cancer	1.46e-06	1.09e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—stomach cancer	1.46e-06	1.09e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—stomach cancer	1.45e-06	1.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—stomach cancer	1.45e-06	1.09e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—stomach cancer	1.45e-06	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	1.45e-06	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—stomach cancer	1.41e-06	1.06e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—stomach cancer	1.4e-06	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—stomach cancer	1.4e-06	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—stomach cancer	1.39e-06	1.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—stomach cancer	1.35e-06	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—stomach cancer	1.35e-06	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—stomach cancer	1.34e-06	1e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—stomach cancer	1.34e-06	9.99e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—stomach cancer	1.32e-06	9.86e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—stomach cancer	1.3e-06	9.75e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—stomach cancer	1.29e-06	9.66e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—stomach cancer	1.29e-06	9.63e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—stomach cancer	1.28e-06	9.57e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—stomach cancer	1.24e-06	9.31e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—stomach cancer	1.23e-06	9.23e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK1—stomach cancer	1.22e-06	9.11e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—stomach cancer	1.2e-06	8.97e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—stomach cancer	1.18e-06	8.86e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—stomach cancer	1.18e-06	8.82e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK1—stomach cancer	1.17e-06	8.78e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—stomach cancer	1.17e-06	8.78e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—stomach cancer	1.15e-06	8.6e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—stomach cancer	1.13e-06	8.48e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—stomach cancer	1.11e-06	8.29e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—stomach cancer	1.06e-06	7.9e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—stomach cancer	1.04e-06	7.75e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—stomach cancer	1.02e-06	7.65e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	1.02e-06	7.62e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—stomach cancer	9.85e-07	7.37e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—stomach cancer	9.77e-07	7.31e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—stomach cancer	9.42e-07	7.05e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—stomach cancer	9.35e-07	7e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—stomach cancer	9.02e-07	6.74e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—stomach cancer	6.38e-07	4.77e-06	CbGpPWpGaD
